Atrium Therapeutics Statistics
Total Valuation
RNA has a market cap or net worth of $219.64 million. The enterprise value is -$42.58 million.
| Market Cap | 219.64M |
| Enterprise Value | -42.58M |
Important Dates
The last earnings date was Thursday, August 13, 2026, after market close.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RNA has 17.11 million shares outstanding.
| Current Share Class | 17.11M |
| Shares Outstanding | 17.11M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 3.04% |
| Owned by Institutions (%) | 90.01% |
| Float | 15.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.13 |
| Forward PS | 219.64 |
| PB Ratio | 1.02 |
| P/TBV Ratio | 1.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.73, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.73 |
| Quick Ratio | 8.38 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -27.80% |
| Weighted Average Cost of Capital (WACC) | 9.29% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -142,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.93 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 12.33 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 62.17 |
| Average Volume (20 Days) | 123,500 |
Short Selling Information
The latest short interest is 3.51 million, so 6.62% of the outstanding shares have been sold short.
| Short Interest | 3.51M |
| Short Previous Month | 3.59M |
| Short % of Shares Out | 6.62% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 20.92 |
Income Statement
In the last 12 months, RNA had revenue of $35.84 million and -$65.99 million in losses. Loss per share was -$3.86.
| Revenue | 35.84M |
| Gross Profit | -20.20M |
| Operating Income | -69.21M |
| Pretax Income | -66.13M |
| Net Income | -65.99M |
| EBITDA | -68.53M |
| EBIT | -69.21M |
| Loss Per Share | -$3.86 |
Balance Sheet
The company has $263.90 million in cash and $1.68 million in debt, with a net cash position of $262.22 million or $15.33 per share.
| Cash & Cash Equivalents | 263.90M |
| Total Debt | 1.68M |
| Net Cash | 262.22M |
| Net Cash Per Share | $15.33 |
| Equity (Book Value) | 214.58M |
| Book Value Per Share | 12.54 |
| Working Capital | 243.54M |
Cash Flow
In the last 12 months, operating cash flow was -$53.19 million and capital expenditures -$3.31 million, giving a free cash flow of -$56.50 million.
| Operating Cash Flow | -53.19M |
| Capital Expenditures | -3.31M |
| Depreciation & Amortization | 685,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -56.50M |
| FCF Per Share | -$3.30 |
Margins
Gross margin is -56.37%, with operating and profit margins of -193.13% and -184.14%.
| Gross Margin | -56.37% |
| Operating Margin | -193.13% |
| Pretax Margin | -184.54% |
| Profit Margin | -184.14% |
| EBITDA Margin | -191.22% |
| EBIT Margin | -193.13% |
| FCF Margin | n/a |
Dividends & Yields
RNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -30.05% |
| FCF Yield | -25.72% |
Analyst Forecast
The average price target for RNA is $25.00, which is 94.70% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $25.00 |
| Price Target Difference | 94.70% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RNA has an Altman Z-Score of 2.27 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.27 |
| Piotroski F-Score | 3 |